Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 445

Similar articles for PubMed (Select 19368957)

1.

Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Strosberg J, Nasir A, Coppola D, Wick M, Kvols L.

Hum Pathol. 2009 Sep;40(9):1262-8. doi: 10.1016/j.humpath.2009.01.010. Epub 2009 Apr 14.

PMID:
19368957
2.

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B.

Cancer. 2008 Jul 15;113(2):256-65. doi: 10.1002/cncr.23549.

3.

Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.

Pape UF, Böhmig M, Berndt U, Tiling N, Wiedenmann B, Plöckinger U.

Ann N Y Acad Sci. 2004 Apr;1014:222-33.

PMID:
15153439
4.
5.

Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center.

Yildiz O, Ozguroglu M, Yanmaz T, Turna H, Serdengecti S, Dogusoy G.

Med Oncol. 2010 Dec;27(4):1050-6. doi: 10.1007/s12032-009-9332-7. Epub 2009 Nov 3.

PMID:
19908171
6.

The significance of CD44 expression in gastrointestinal neuroendocrine tumors.

Lai CH, Shan YS, Sy ED, Hsieh YH, Tsai HW, Lee JC, Lin PW.

Hepatogastroenterology. 2005 Jul-Aug;52(64):1071-6.

PMID:
16001632
7.

Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.

Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A.

World J Surg. 2014 Jun;38(6):1353-61. doi: 10.1007/s00268-014-2451-0.

PMID:
24493070
8.

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B.

Endocr Relat Cancer. 2008 Dec;15(4):1083-97. doi: 10.1677/ERC-08-0017. Epub 2008 Jul 4.

9.

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G.

Endocr Relat Cancer. 2005 Dec;12(4):1083-92.

10.

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I.

J Cancer Res Clin Oncol. 2012 Mar;138(3):397-403. doi: 10.1007/s00432-011-1107-9. Epub 2011 Dec 8.

PMID:
22160160
11.

[Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].

Brüwer M, Pahlov-Nejad T, Herbst H, Senninger N, Schürmann G.

Zentralbl Chir. 2003 Aug;128(8):656-62. German.

PMID:
12931261
12.

Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.

Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E.

Endocr Relat Cancer. 2009 Jun;16(2):585-97. doi: 10.1677/ERC-08-0301. Epub 2009 Feb 24.

13.

Surgical treatment of gastrointestinal neuroendocrine tumors.

Fendrich V, Bartsch DK.

Langenbecks Arch Surg. 2011 Mar;396(3):299-311. doi: 10.1007/s00423-011-0741-7. Epub 2011 Feb 1. Review.

PMID:
21279821
14.

Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.

Farrell JM, Pang JC, Kim GE, Tabatabai ZL.

Cancer Cytopathol. 2014 Oct;122(10):770-8. doi: 10.1002/cncy.21457. Epub 2014 Jul 9.

PMID:
25044931
15.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

16.

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group.

J Clin Oncol. 2003 Jul 15;21(14):2689-96.

PMID:
12860945
17.

[Roles of risk assessment and Ki-67 index in judging prognostic of gastrointestinal stromal tumors].

Liang YM, Li XH, Chen W.

Zhonghua Yi Xue Za Zhi. 2008 Apr 15;88(15):1041-5. Chinese.

PMID:
18754437
18.

Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.

Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z.

Am J Surg Pathol. 2015 Jan;39(1):13-24. doi: 10.1097/PAS.0000000000000341.

PMID:
25353284
19.

Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.

McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, Schulick RD, Edil BH, Hruban RH.

Am J Surg Pathol. 2013 Nov;37(11):1671-7. doi: 10.1097/PAS.0000000000000089.

20.

Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.

Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A.

J Hepatobiliary Pancreat Surg. 2009;16(5):639-47. doi: 10.1007/s00534-009-0099-1. Epub 2009 Apr 14.

PMID:
19365596
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk